Whole-Genome Screening Expands the Gene Map of Cardiovascular Disease
Rare coding variation is reshaping how cardiovascular disease is mapped at the gene level, and this preprint pushes that map further than earlier burden studies built on narrower variant filters. Using whole-genome sequencing data from up to 483,311 UK Biobank participants, investigators examined six genetic ancestry groups and eight cardiovascular phenotype groups in a design built to capture both known and previously unrecognized gene-phenotype relationships. The analysis blended state-of-the-art missense classification with predicted pathogenic germline variants, an approach that matters because the way variants are selected can change whether a signal looks weak, strong, or absent altogether.
The cohort scale is the first striking feature. So is the breadth of the phenotype framework.
Across the combined-sex and sex-stratified analyses, the study identified 86 exome-wide significant gene-phenotype associations. Of these, 40 were established associations and 46 were novel. The result does not just add to the list of implicated genes; it reorders the confidence attached to specific pathways by showing which relationships survive more refined variant calling and which emerge only after sex-specific modeling and cross-ancestry meta-analysis.
Novel Signals Point to Arrhythmia, Conduction, and Atherosclerotic Biology
Several of the new associations are especially notable because they connect genes to phenotypes with clear clinical relevance. EHMT2 was linked with atrial fibrillation, P2RX1 with arrhythmias, and P2RY4 with complete atrioventricular block. In female participants, NOSTRIN was associated with atherosclerotic heart disease. These are not random pairings; they cluster around biology that plausibly influences electrical stability, endothelial function, and vascular disease susceptibility.
The purinergic pathway stands out across the findings. P2RX1 and P2RY4 sit in a signaling system that regulates how cells respond to extracellular nucleotides, a mechanism with obvious relevance to vascular tone and cardiac electrophysiology. In parallel, NOSTRIN implicates endothelial nitric oxide regulation, a route that can shape vasomotor behavior and vascular health. The study also points to vascular wall biology as a recurring theme, reinforcing the idea that inherited risk is distributed across tissue-level processes rather than confined to a single molecular axis.
Sex-Stratified Analysis Reveals Signals That Would Otherwise Be Missed
The female-specific association between NOSTRIN and atherosclerotic heart disease is one of the clearest reminders that sex-stratified analysis is not a statistical garnish. It can reveal genuine biology that is diluted or obscured in pooled models. Cardiovascular genetic studies have long struggled with the possibility that some inherited effects differ by sex because of hormonal influences, vascular remodeling patterns, differential exposure to cardiometabolic risk factors, or differences in disease expression. This dataset adds concrete evidence that sex-aware testing can expose phenotype links that a combined-sex model may soften.
A single sex-agnostic estimate can flatten clinically important heterogeneity. Here, the stratified framework did the opposite: it sharpened it.
Cardiometabolic Adjustment Broadened the Signal Set
Sensitivity analyses that adjusted for cardiometabolic traits changed the association landscape in two directions. After adjustment, 60 associations remained exome-wide significant, while 18 additional associations emerged. Among the newly surfaced signals were CDH11, PARVA, and ADAMDEC1 in atherosclerosis-related phenotypes. This pattern suggests that some gene-phenotype relationships are easier to see once shared cardiometabolic confounding is accounted for, while others are robust enough to remain significant even without that correction.
The direction of change is important. It indicates that the architecture of cardiovascular inherited risk is not static; it shifts depending on how much of the background cardiometabolic burden is statistically absorbed. Genes that appear hidden under one analytic lens can become visible under another, especially when the outcome sits close to metabolic disease, vascular injury, and plaque biology.
Penetrance Estimates Depend on Which Variants Enter the Burden Test
Beyond association counts, the study examined penetrance among qualifying-variant carriers and assessed genetic prevalence across eight ancestry groups. Those analyses matter for the practical interpretation of inherited susceptibility because a gene with a strong burden signal does not automatically translate into high absolute disease risk for every carrier. Variant selection shapes who is counted as a carrier, which in turn shapes the penetrance estimate and the apparent clinical weight of the gene.
This is one of the central messages of the preprint: classification rules are not merely technical details. Different filters can alter the denominator, change the apparent expressivity of a variant class, and shift whether a gene looks highly penetrant or only moderately informative. For cardiovascular genetics, where rare variants are often used to infer familial risk, that distinction affects how results are translated into counseling, risk stratification, and downstream research design.
Why the Biological Pathways Matter at the Bedside
The findings converge on several biologic themes with plausible bedside consequences. Purinergic signaling affects how vascular and myocardial cells communicate under stress. Endothelial nitric oxide regulation shapes vessel behavior and may influence atherosclerotic vulnerability. Vascular wall biology remains a core determinant of how plaques form, evolve, and destabilize. These pathways do not replace conventional risk factors, but they may help explain why some patients develop arrhythmia, conduction disease, or atherosclerosis despite similar clinical profiles.
The study’s value lies in its breadth and its analytic discipline. Whole-genome sequencing across a very large biobank, multi-ancestry comparison, and sex-stratified modeling produced a gene-level map that is more detailed than earlier efforts built on smaller or narrower datasets. It also shows how cardiovascular genetics is moving from simple gene lists toward pathway-aware interpretation, where the same phenotype can be shaped by different genes in different populations or in different sexes.
A Preprint With Scale, but Not a Clinical Verdict
This remains a preprint and has not undergone peer review. The findings should therefore be treated as a high-value research resource rather than a basis for clinical decision-making. Even so, the data provide a broad catalog of gene-phenotype associations that can guide replication work, functional follow-up, and future risk-model development.
The strongest immediate limitation is also the most instructive one: the interpretation of inherited cardiovascular risk depends heavily on variant definition, ancestry context, and sex-specific modeling. Without those layers, a substantial fraction of the signal would either be missed or misread. Future work will need to test which of these associations replicate in independent cohorts and which translate into measurable changes in prediction or disease classification.